4 completed. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow mavacamten: new trials by email Literature Review of mavacamten trials Research Report on mavacamten
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT mavacamten - Heart Failure With Preserved Ejection Fraction | Phase 2 | Completed | Bristol-Myers Squibb | 30 | 2021-03-30 | 2025-03-20 |
| A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM mavacamten - Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Bristol-Myers Squibb | 314 | 2018-09-27 | 2026-02-20 |
| Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER mavacamten - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Bristol-Myers Squibb | 13 | 2018-04-26 | 2025-01-09 |
| A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) mavacamten, Placebo - Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | Completed | MyoKardia, Inc. | 59 | 2018-03-30 | 2022-08-09 |
Cardiomyopathy, Hypertrophic (2) · Cardiomyopathy, Familial Restrictive, 3 (1)
Bristol-Myers Squibb (3) · MyoKardia, Inc. (1)
United States (4) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Portugal (1) · Spain (1) · United Kingdom (1)
PMID 32466879, PMID 38176782, PMID 38591260, PMID 39217450, PMID 39347697, PMID 42636950